Genor Biopharma Co., Ltd.

Quick facts

Phase 3 pipeline

• GB242 · Diabetes
  GB242 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders.
• GB491 combined with Letrozole · Oncology
  GB491 combined with Letrozole works by inhibiting a molecular target (likely CDK4/6 or similar cell-cycle regulator) to arrest tumor cell proliferation, while Letrozole blocks aromatase to reduce estrogen production in hormone receptor-positive breast cancer.
• GB491+ Fulvestrant · Oncology
  GB491 is a selective estrogen receptor degrader (SERD) that works synergistically with fulvestrant to degrade estrogen receptors and block estrogen signaling in hormone receptor-positive breast cancer cells.
• Placebo combined with Letrozole · Oncology
  Letrozole is an aromatase inhibitor that blocks estrogen production in postmenopausal women, combined with placebo in this trial design.

Phase 2 pipeline

• GB226

Phase 1 pipeline

• [14C]GB491
• GB222
• GB224 10mg
• GB224 30mg
• GB261
• GB263T
• GB268
• Geptanolimab Injection 280mg, q3w

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Genor Biopharma Co., Ltd. portfolio CI brief
• Genor Biopharma Co., Ltd. pipeline updates RSS